Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy
- Vito LorussoAffiliated withOncology Unit, Vito Fazzi Hospital Email author
- , Marianna GiampagliaAffiliated withOncology Unit, Vito Fazzi Hospital
- , Luciana PetrucelliAffiliated withOncology Unit, Vito Fazzi Hospital
- , Valeria SaracinoAffiliated withOncology Unit, Vito Fazzi Hospital
- , Tania PerroneAffiliated withScientific Department, Italfarmaco
- , Antonio GnoniAffiliated withOncology Unit, Vito Fazzi Hospital
The goal of pharmacological prophylaxis of chemotherapy-induced nausea and vomiting (CINV) should be the elimination of both nausea and vomiting symptoms during all planned chemotherapy cycles. The aim of this study was to assess the efficacy of a single dose of palonosetron and dexamethasone to prevent CINV and to guarantee an adequate food intake (FI) in patients receiving several cycles of multiple day-based chemotherapy (MD-CT).
Patients with advanced cancer but without a compromised nutritional status (bone mass index ≥ 18.5) were treated with 0.25 mg palonosetron plus 20 mg dexamethasone before MD-CT. The MD-CT regimen was either epirubicin plus ifosfamide or paclitaxel plus cisplatin and ifosfamide. Nausea, vomiting, and FI were monitored in a 7-day diary. Complete response (CR: no vomiting and no rescue therapy) was the primary endpoint, while complete control (CC: CR and no more than mild nausea) and the evaluation of FI were secondary endpoints. The endpoints were evaluated during the overall timescale (0–168 h) of the chemotherapy regimen.
Fifty patients were enrolled, 80% of whom achieved CR and 78% achieved CC. During the six chemotherapy cycles, CR and CC ranged from 76% to 88% and from 62% to 88%, respectively. Moreover, patients with CR had a significantly (p < 0.0001) higher weekly food intake compared with patients not achieving CR.
This trial was the first to assess the efficacy of palonosetron and dexamethasone for the prevention of both nausea and vomiting in patients receiving multiple cycles of MD-CT. In this trial, the ability of patients to intake an adequate amount of food each week was correlated with nausea, thus providing clinicians with an objective parameter for the measurement of the effects of nausea. A single dose of palonosetron and dexamethasone was able to prevent CINV in most patients receiving 3 days of chemotherapy during all planned chemotherapy cycles.
KeywordsChemotherapy-induced nausea and vomiting (CINV) Food intake Multiple day chemotherapy Multiple cycles Palonosetron
- Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Supportive Care in Cancer
Volume 20, Issue 12 , pp 3241-3246
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Chemotherapy-induced nausea and vomiting (CINV)
- Food intake
- Multiple day chemotherapy
- Multiple cycles
- Industry Sectors